ARCHIVES

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Offers Grants For Conferences

May 1, 1987

‘Helping Smokers Quit’ Program Launched By NCI, Pharmacist Group

June 27, 1986

New Drugs Improve Outlook For Bone Marrow Cancer

March 31, 2006

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

October 26, 2001

Rare Lung Disease Raises Risk Of Meningiomas

October 26, 2001

ASCO Places Ad To Urge Increase In Research Funding.

June 13, 2008